Test a tailored immune plan soon after a heart transplant
Part of Heart & circulation, Immune system & allergy clinical trials.
This trial checks whether using heart-monitoring blood tests and biopsy results can help customize (optimize) immune-suppression medication soon after your transplant. It aims to keep the transplanted heart safe while avoiding over- or under-treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are at least 18 years old and received a heart transplant within the last 2 weeks
- You plan to take a specific “baseline” immune medicine plan after transplant: prednisolone, tacrolimus, and mycophenolate
- If you can become pregnant, you agree to use effective birth control during the study and for 3 months after
- You are willing and able to sign consent and follow all study instructions (including clinic visits and tests)
- You cannot be in certain transplant situations (for example, multi-visceral transplants)
- You must be able to complete required heart tests, including AlloSure/AlloMap testing and protocol biopsies
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether a drug called belatacept can safely help your body accept a new heart without rejecting it, and may reduce the need for other strong immune-suppressing medicines. If you are getting a heart transplant for the first time and have certain immune markers, this trial may be an option for you.
This study tests whether combining everolimus with a lower dose of a standard anti-rejection drug (calcineurin inhibitor) can help heart transplant patients in Korea have fewer side effects while keeping their new heart healthy.
This trial is studying whether a blood test that measures small molecules called microRNAs can help doctors personalize the medicines used to prevent rejection after a heart transplant. If you qualify, you would help researchers learn how to better match immunosuppression to each patient's needs.
This trial uses precise, personalized approaches to manage heart transplant recipients. It involves taking a small heart muscle sample (a biopsy) to monitor for rejection or routine checks.
This trial studies whether belatacept can be used after a heart transplant to help protect kidney function over time. It focuses on people who already have (or are at risk for) worsening kidney function after transplant, while avoiding those with certain infections or rejection concerns.
This trial studies whether belatacept, an anti-rejection medicine given by IV, can work for people receiving their first heart transplant. It aims to see if it prevents rejection safely for patients and whether it fits better than standard approaches for certain candidates.
Hear when a new Heart Transplant trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.